Robert Olstein’s Charles River Laboratories CRL Stock Holding History

Robert Olstein’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-48,235	Closed	-$5.28M	–	114
2017 Q4	$5.28M	Sell	48,235 -11,877	-20%	-$1.29M	0.67%	65
2017 Q3	$6.49M	Sell	60,112 -17,023	-22%	-$1.75M	0.84%	49
2017 Q2	$7.8M	Sell	77,135 -30,920	-29%	-$2.85M	0.99%	40
2017 Q1	$9.72M	Sell	108,055 -27,980	-21%	-$2.38M	1.24%	27
2016 Q4	$10.4M	Buy	136,035 +50,410	+59%	+$3.83M	1.34%	24
2016 Q3	$7.14M	Buy	85,625 +29,724	+53%	+$2.49M	0.94%	48
2016 Q2	$4.61M	Buy	55,901 +31,615	+130%	+$2.6M	0.62%	78
2016 Q1	$1.84M	Buy	+24,286	New	+$1.8M	0.25%	97
2015 Q1	–	Sell	-32,000	Closed	-$2.04M	–	119
2014 Q4	$2.04M	Sell	32,000 -89,000	-74%	-$5.58M	0.25%	111
2014 Q3	$7.23M	Sell	121,000 -12,000	-9%	-$687K	0.94%	50
2014 Q2	$7.12M	Buy	133,000 +52,000	+64%	+$2.85M	0.96%	46
2014 Q1	$4.89M	Sell	81,000 -88,000	-52%	-$5.13M	0.67%	78
2013 Q4	$8.96M	Sell	169,000 -7,000	-4%	-$352K	1.28%	16
2013 Q3	$8.14M	Hold	176,000	–	–	1.25%	16
2013 Q2	$7.22M	Buy	+176,000	New	+$7.54M	1.16%	27

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Robert Olstein's CRL Position: Q1 2018 in Review

Robert Olstein sold out of Charles River Laboratories (CRL) in Q1 2018, closing a stake of 48,235 shares — an estimated $5.28M sold.

Robert Olstein first reported a position in CRL in Q2 2013 and held it in 15 quarters. The position peaked at $10.4M in Q4 2016. 333 funds tracked by Wall St. Rank hold CRL as of Q1 2018.

Robert Olstein reported no remaining Charles River Laboratories position as of Q1 2018 after selling out during the quarter.
Robert Olstein sold 48,235 Charles River Laboratories shares in Q1 2018, an estimated $5.28M.
Robert Olstein first reported a position in Charles River Laboratories in Q2 2013 and held it in 15 quarters.
Robert Olstein's Charles River Laboratories position peaked at $10.4M in Q4 2016.
333 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2018.

Based on Olstein Capital Management's 13F filing for Q1 2018, filed 4 May 2018.